Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis

Rituximab combined with chemotherapy is the first-line induction therapy of CD20 positive B-cell non-Hodgkin lymphomas (CD20(+) B-NHL). Recently new anti-CD20 monoclonal antibodies (mAbs) have been developed, but their efficacy and safety compared with rituximab are still controversial. We searched...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Chengxin, Wu, Guixian, Huang, Xiangtao, Ma, Yanni, Zhang, Yali, Song, Qiuyue, Xie, Mingling, Sun, Yanni, Huang, Yarui, Huang, Zhen, Hou, Yu, Xu, Shuangnian, Chen, Jieping, Li, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864901/
https://www.ncbi.nlm.nih.gov/pubmed/33547368
http://dx.doi.org/10.1038/s41598-021-82841-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864901/
https://www.ncbi.nlm.nih.gov/pubmed/33547368
http://dx.doi.org/10.1038/s41598-021-82841-w

Ejemplares similares